Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4821-

  Burington, Bart ^a   Barlogie, Bart ^b   Zhan, Fenghuang ^b   Crowley, John ^a   Shaughnessy Jr , John D ^b  

^a Fred Hutchinson Cancer Research Center

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR CELL; CYTOSKELETON; DNA MICROARRAY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MORTALITY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYTOSKELETON; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, STATISTICAL; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 51049090172     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4568     Document Type: Article

References (43)

1. Barlogie B, Shaughnessy J, Munshi N, Epstein J. Plasma Cell Myeloma. In: Beutler E, Lichtman M, Coller B, Kipps T, editors. William's hematology. 6th ed. New York: McGraw-Hill, Inc; 1999.
2. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
3. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
4. Richardson PG, Schlossman R, Hideshima T, Anderson KC. New treatments for multiple myeloma. Oncology (Huntingt) 2005;19:1781-92: discussion 92, 95-7.
5. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108: 2020-8.
6. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
7. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34:85-90.
8. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005;7:375-86.
9. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005;105:821-6.
10. Holleman A, Cheok MH, den Boer ML, et al. Geneexpression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.
11. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.
12. Zandecki M, Facon T, Preudhomme C, et al. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leuk Lymphoma 1995;18: 497-503.
13. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99: 1745-57.
14. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
15. Shaughnessy JD, Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109: 2276-84.
16. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
17. Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol 2004;41:1-5.
18. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.
19. Andersen NF, Standal T, Nielsen JL, et al. Syndecan- 1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005;128:210-7.
20. Shaughnessy J, Fenghuang Z, Kordsmeier B, Tian E. Smith R, Barlogie B. Gene expression profiling of the bone marrow microenvironment in patients with multiple myeloma, monoclonal gammopathy of undetermined significance and normal healthy donors. Blood 2002;100.
21. Colla S, Zhan F, Xiong W, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007;109:4470-7.
22. Knobloch J, Shaughnessy JD, Jr., Ruther U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 2007; 21:1410-21.
23. Chen W, Yazicioglu M, Cobb MH. Characterization of OSR1, a member of the mammalian Ste20p/germinal center kinase subfamily. J Biol Chem 2004;279: 11129-36.
24. Neefjes JJ, Momburg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993;261: 769-71.
25. Carrasco DR, Tonon G, Huang Y, et al. Highresolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313-25.
26. Anselmo AN, Earnest S, Chen W, et al. WNK1 and OSR1 regulate the Na+, K+, 2CI - cotransporter in HeLa cells. Proc Natl Acad Sci U S A 2006;103: 10883-8.
27. Chen W, White MA, Cobb MH. Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway. J Biol Chem 2002;277:49105-10.
28. Parrini MC, Lei M, Harrison SC, Mayer BJ. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rad. Mol Cell 2002;9:73-83.
29. Wang B, Xiao Y, Ding BB, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003;4:19-29.
30. Wong K, Ren XR, Huang YZ, et al. Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell 2001;107:209-21.
31. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
32. Yang Y, Macleod V, Miao HQ, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007;282:13326-33.
33. Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007;109:4914-23.
34. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003;63: 8749-56.
35. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000;95:388-92.
36. Steigemann P, Molitor A, Fellert S, Jackie H, Vorbruggen G. Heparan sulfate proteoglycan syndecan promotes axonal and myotube guidance by slit/robo signaling. Curr Biol 2004;14:225-30.
37. Annunziata C, Davis RE, Demchenko Y. Frequent engagement of the classical and alternative NF-kB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. In press.
38. κB activation. Biol Chem 2006; 387:79-86.
39. κB activity by multiple signaling pathways requires PAK1. J Biol Chem 2000; 275:19693-9.
40. κB. Blood 2001;97:2702-7.
41. Cusick JK, Xu LG, Bin LH, Han KJ, Shu HB. Identification of RELT homologues that associate with RELT and are phosphorylated by OSR1. Biochem Biophys Res Commun 2006;340:535-43.
42. Graham DK, Salzberg DB, Kurtzberg J, et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 2006;12:2662-9.
43. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5: 810-6.